Company: STAA
Filing Date: 2025-10-10
Form Type: DFAN14A
Source: 0001213900-25-098172
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-10
Form: DFAN14A
Chunk 1
---
23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special
Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”)
and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies from the Company’s stockholders
for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURTIES AND EXCHANGE COMMISSION (THE “SEC”) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The Definitive
Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s stockholders and will
be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on September 26, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale

Raises Concerns About Whether the Board Fulfilled Its Fiduciary Duty of Care in Doubling Down on Its Commitment to Proposed Transaction

Renewed Support Comes After Stunning Revelation STAAR CEO and Chair Failed to Disclose Inbound Interest in Acquiring the Company to Rest of Board</div>

New York--(BUSINESS WIRE)--Broadwood
Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of
Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA).
Broadwood, which owns 27.5% of STAAR’s outstanding common shares, continues to urge its fellow shareholders to vote on its GREEN
Proxy Card “AGAINST” the proposed acquisition